gajus-shutterstock-com
Gajus / Shutterstock.com
31 March 2016Big PharmaKatie Hutchinson

A sense of relief: enforcing second medical use patents

In the last year the English courts have produced several judgments on infringement of second medical use claims as part of the continuing litigation between Warner-Lambert (Pfizer) and Actavis and Mylan. While there are still questions to be answered on determining infringement of second medical use patents, there are some practical steps which patentees and future competitors can consider taking that may assist in trying to reach a non-contentious solution before the launch of any potentially infringing medicine. There is also some guidance from the courts on what relief patentees can expect the courts to provide if an infringement action relating to a second medical use patent is successful.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
16 March 2026   Research from the International Trademark Association finds in-house counsel taking on more strategic work while facing shrinking budgets, prompting a shift towards alternative billing and greater use of AI.
Big Pharma
10 March 2026   UK government funding will support the London-based IP crime unit until 2029, as EUIPO and European authorities step up efforts to tackle unsafe counterfeits.
Big Pharma
11 February 2026   Courts on both sides of the Atlantic recorded a flurry of settlements this week, as Astellas, GSK, and Alexion drew a line under long-running disputes with generic rivals.